Design Therapeutics financials
$12.62+2.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | -$35.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-1.22 | $-0.88 | $-1.19 | $-1.14 | $-0.77 |
| EBITDA | -$78.8M | -$61.8M | -$77.7M | -$67.1M | -$35.7M |
| Operating cash flow | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M |
| Free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M | -$30.9M |
| Diluted shares | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $16.9M | $22.6M | $21.2M | $26.5M | $298.6M |
| Short-term investments | $203.0M | $222.9M | $260.6M | $303.9M | $85.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M |
| Shareholders' equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology